stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.01
1.83
+2.17%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Gross margin
Abivax SA Sponsored ADR's gross margin over the twelve months to 31 December 2022 was 0.00%. Over the past ten years it has ranged from 0.00% (fiscal 2022) to 0.00% (fiscal 2022) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Dec 2022 | 0.00% | 0.00 |
| Jun 2022 | 0.00% | 0.00 |
| Dec 2021 | 0.00% | 0.00 |
| Jun 2021 | 0.00% | — |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Gross margin against peers
| Company | Gross margin |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 100.0% |
| PRAX Praxis Precision Medicines, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. compare | 100.0% |
| CORT Corcept Therapeutics Incorporated compare | 98.5% |
| AXSM Axsome Therapeutics, Inc. compare | 93.3% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 88.2% |
| ORKA Oruka Therapeutics, Inc. compare | 0.00% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| ABVX Abivax SA Sponsored ADR | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue